Mark Agnel Frederick Dawson, Cigall Kadoch, Michelle Monje receive MSK’s 2023 Paul Marks Prize

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

New research on the possibility to kill TNBCs by hijacking signals that normally drive mammary gland involution was released in Nature.

October 11, 2024

Vol.50 No.38

Conversation with The Cancer Letter

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.

October 04, 2024

Vol.50 No.37

By Claire Marie Porter

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

In Brief

Cigall Kadoch wins $250,000 Blavatnik National Award

Cigall Kadoch was named the laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences for her work in cancer biology.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Tumors are able to form with no DNA mutations, fly study shows

Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.

September 13, 2024

Vol.50 No.34

By Jacquelyn Cobb

Mark Agnel Frederick Dawson, Cigall Kadoch, Michelle Monje receive MSK’s 2023 Paul Marks Prize

YOU MAY BE INTERESTED IN

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Cigall Kadoch wins $250,000 Blavatnik National Award

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Tumors are able to form with no DNA mutations, fly study shows

Renew today!

Subscriber content

Login

Mark Agnel Frederick Dawson, Cigall Kadoch, Michelle Monje receive MSK’s 2023 Paul Marks Prize

YOU MAY BE INTERESTED IN

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Cigall Kadoch wins $250,000 Blavatnik National Award

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Tumors are able to form with no DNA mutations, fly study shows

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies